• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Arrowhead Pharmaceuticals (ARWR) In Focus As Brain Delivery Breakthrough Fuels Undervalued View

    Simply Wall St·10/20/2026 02:29:06
    Listen to the news

    Arrowhead Pharmaceuticals (ARWR) is back in focus after interim Phase 1/2a data for ARO-MAPT showed deep reductions in cerebrospinal fluid tau and the first clinical validation of its blood brain barrier RNAi delivery platform.

    Recent trading tells a mixed story for Arrowhead Pharmaceuticals. The share price has pulled back, with the 30 day share price return down 13.91% and the 90 day share price return down 23.20%. At the same time, the 1 year total shareholder return is 48.77% and the 3 year total shareholder return is 131.79%. This suggests the latest ARO-MAPT and plozasiran updates are landing on a stock that has already rewarded long term holders even as shorter term momentum has cooled.

    Capitalize on the renewed interest in Arrowhead Pharmaceuticals by scanning a curated set of RNA and biotech opportunities across our 20 high quality undiscovered gems that may be flying under most investors’ radar.

    Arrowhead Pharmaceuticals now carries both a sharp pullback and strong multi year gains in its rearview mirror. Is the bigger opportunity still ahead, or has most of the easy upside already passed by?

    Most Popular Narrative: 48% Undervalued

    Arrowhead Pharmaceuticals closed at $57.23, while the most followed valuation framework assigns a fair value of $110.18, which places current trading levels well below that narrative estimate and puts extra weight on the pipeline and partnership story behind the numbers.

    Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, is presented as positioning the company to capitalize on rising demand for new treatments driven by an aging population and increasing prevalence of chronic and genetic diseases. This is described as a factor that could significantly accelerate revenue growth as approvals and launches materialize. Progress in RNAi delivery technology, pipeline breadth in both prevalent and rare or orphan indications, and first-mover potential in CNS and adipose tissue RNAi are cited as expanding Arrowhead's competitive edge as advancements in genomics and precision medicine increase the feasibility and personalization of RNAi therapies. These factors are viewed as supporting stronger projected net margins and long-term earnings growth if adoption broadens.

    See why 14 investors see Arrowhead Pharmaceuticals as 48% undervalued.

    Result: Fair Value of $110.18 (UNDERVALUED)

    Still, Arrowhead Pharmaceuticals relies heavily on milestone and collaboration payments, and higher late stage trial and commercial costs could strain cash flow if partner or regulatory timelines slip.

    Find out about the key risks to this Arrowhead Pharmaceuticals narrative.

    Next Steps

    Mixed signals usually create the most debate, so take a fresh look at Arrowhead Pharmaceuticals, weigh both the potential upside and the known issues, then stress test that view against the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

    If Arrowhead Pharmaceuticals has your attention, broaden your watchlist now by lining up fresh candidates that match your risk comfort, income needs, and value focus.